Gan & Lee Pharmaceuticals Gets US FDA Approval for Clinical Trials of Weight Control Drug

MT NewswiresDec 13 11:36

Express News | Gan & Lee Pharmaceuticals: The USA subsidiary's GZR18 injection has received FDA clinical trial approval.

BreakingsDec 12 17:46

The 76-year-old actual controller pledged shares to repay debts, while leading insulin players accelerate their overseas expansion.

The company has experienced ups and downs since its listing more than four years ago, initially basking in the glory of a trillion yuan market cap, but later reorganized its strategy under policy influence. In 2023, the company's controlling shareholder Gan Zhongru "swept" the private placement, and deployed work such as going global, research and development, and investments. Whether the former glory can be reproduced remains to be seen, waiting for time to provide the answer. Gan Zhongru, the controlling shareholder in his seventies and already over seventy, still faces considerable pressure. According to the announcement, the company's shareholders

China InvestorsDec 3 18:01

Express News | 7 stocks have their equity registered today, with gan & lee pharmaceuticals, jianlin household, and ningbo tip rubber technology having the highest dividend payout.

BreakingsNov 29 07:48

gan & lee pharmaceuticals (603087.SH) announced a third quarter equity distribution: 0.5 yuan per share.

Gan & Lee Pharmaceuticals (603087.SH) issued an announcement, implementing the equity distribution for the third quarter of 2024: A shares per...

Zhitong FinanceNov 25 17:50

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

PR NewswireNov 12 19:00